Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: Possible role in agranulocytosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 3, 1997, Pages 1375-1382

  Williams, Dominic P ^a   Pirmohamed, Munir ^a   Naisbitt, Dean J ^a   Maggs, James L ^a   Park, B Kevin ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CLOZAPINE; GLUTATHIONE; NORCLOZAPINE;

AGRANULOCYTOSIS; ARTICLE; CYTOTOXICITY; DRUG ACTIVATION; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL;

ADULT; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; CELL SURVIVAL; CLOZAPINE; GLUTATHIONE; HORSERADISH PEROXIDASE; HUMANS; MALE; NEUTROPHILS; PEROXIDASE;

EID: 0031471159     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. ALVIR, J. M. J. AND LIEBERMAN, J. A.: A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States Experience. J. Clin. Psychopharmacol. 14: 87-89, 1994.
2. BABIOR, B. M.: The respiratory burst of phagocytes. J. Clin. Invest. 73: 599-601, 1984.
3. BALDESSARINI, R. J. AND FRANKENBURG, F. R.: Clozapine: A novel antipsychotic agent. N. Engl. J. Med. 324: 746-754, 1991.
4. BRACH, M. A., DE VOS, S., GRUSS, H. J., HERMANN, F.: Prolongation of survival of human polymorphonuclear PMN by granulocyte-macrophage colony-stimulating-factor is caused by inhibition of programmed cell death. Blood 80: 2920-2925, 1992.
5. CORCORAN, G. B., FIX, L., JONES, D. P., MOSLEN, M. T., NICOTERA, P., OBERHAMMER, F. A. AND BUTTYAN, R.: Apoptosis: Molecular control point in toxicity. Toxicol. Appl. Pharmacol. 128: 169-181, 1994.
6. COTGREAVE, I. A. AND MOLDEUS, P.: Methodologies for the application of monobromobimane to the simultaneous analysis of soluble and protein thiol components of biological systems. J. Biochem. Biophys. Methods 13: 231-249, 1986.
7. EASTMOND, D. A., SMITH, M. T., RUZO, L. O. AND ROSS, D.: Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase. Mol. Pharmacol. 30: 674-679, 1986.
8. FISCHER, V., HAAR, J. A., GREINER, L., LLOYD, R. V. AND MASON, R. P.: Possible role of free radical formation in clozapine (Clozaril)-induced agranulocytosis. Mol. Pharmacol. 40: 846-853, 1991.
9. GAUCH, R. AND MICHAELIS, W.: The metabolism of 8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (clozapine) in mice, dogs and human subjects. Il Farmaco. 26: 667-681, 1971.
10. GERSON, S. L., ARCE, C. AND MELTZER, H. Y.: N-Desmethylclozapine: A clozapine metabolite that suppresses haemopoiesis. Br. J. Haematol. 86: 555-561, 1994.
11. KANE, J., HONIGFELD, G., SINGER, J. AND MELTZER, H.: Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 45: 789-796, 1988.
12. LIEBERMAN, J. A. AND SAFFERMAN, A. Z.: Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatr. Q. 63: 51-70, 1992.
13. LIU, Z. C. AND UETRECHT, J. P.: Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to cells. J. Pharmacol. Exp. Ther. 275: 1476-1483, 1995.
14. MAGGS, J. L., WILLIAMS, D., PIRMOHAMED, M. AND PARK, B. K.: The metabolic formation of reactive intermediates from clozapine: A drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 275: 1463-1475, 1995.
15. O'BRIEN, M. L. AND TEW, K. D.: Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer 32A: 967-978, 1996.
16. PARK, B. K., PIRMOHAMED, M., KITTERINGHAM, N. R.: Idiosyncratic drug reactions: A mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34: 377-395, 1992.
17. PARK, B. K., PIRMOHAMED, M., KITTERINGHAM, N. R.: The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacol. Ther. 68: 385-424, 1995.
18. PIRMOHAMED, M., TEMPLETON, E., BRECKENRIDGE, A. M. AND PARK, B. K.: In vitro bioactivation of clozapine to a chemically reactive metabolite by human and mouse liver microsomes. Br. J. Clin. Pharmacol. 34: 168P, 1992.
19. PIRMOHAMED, M., WILLIAMS, D., MADDEN, S., TEMPLETON, E. AND PARK, B. K.: Metabolism and bioactivation of clozapine by human liver in vitro. J. Pharmacol. Exp. Ther. 272: 984-990, 1995.
20. PIRMOHAMED, M., WILLIAMS, D., TINGLE, M. D., BARRY, M., KHOO, S. H., O'MAHONY, C., WILKINS, E. G. L., BRECKENRIDGE, A. M. AND PARK, B. K.: Intracellular glutathione in the peripheral blood cells of HIV-infected patients: Failure to show a deficiency. AIDS 10: 501-507, 1996.
21. PIRMOHAMED, M. AND PARK, B. K.: Mechanism of action of clozapine-induced agranulocytosis: current status of research and implications for drug development. CNS Drugs 7: 139-158, 1997.
22. POLLMACHER, T., HINZESELCH, D. AND MULLINGTON, J.: Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol. 16: 403-409, 1996.
23. RILEY, R. J., LAMBERT, C., MAGGS, J. L., KITTERINGHAM, N. R. AND PARK, B. K.: An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br. J. Clin. Pharmacol. 26: 577-588, 1988.
24. SAFFERMAN, A. Z., LIEBERMAN, J. A., ALVIR, J. J. AND HOWARD, A.: Rechallenge in clozapine-induced agranulocytosis. Lancet 339: 1296-1297, 1992.
25. SAYERS, A. AND AMSLER, H.: In Pharmacological and biochemical properties of drug substances, ed. by Goldberg, M. American Pharmaceutical Association. Washington, D.C.: 18-27, 1997.
26. SPERNER-UNTERWEGER, B., GAGGL, S., FLEISCHHACKER, W. W., BARNAS, C., HEROLD, M. AND GEISSLER, D.: Effects of clozapine on hematopoiesis and the cytokine system. Biol. Psychiatry 34: 536-543, 1993.
27. SPIELBERG, S. P.: Acetaminophen toxicity in human lymphocytes in vitro. J. Pharmacol. Exp. Ther. 213: 395-398, 1980.
28. SUBOTICANEC, K., FOLNEGOVIC-SMALC, V., KORBAR, M., MESTROVIC, B. AND BUZINA, R.: Vitamin C status in chronic schizophrenia. Biol. Psychiatry 28: 959-966, 1990.
29. TAKEDA, Y., WATANABE, H., YONEHARA, S., YAMASHITA, T., SAITO, S. AND SENDO, F.: Rapid acceleration of neutrophil apoptosis by tumor-necrosis-factor-alpha. Int. Immunol. 5: 691-694, 1993.
30. TSCHEN, A. C., RIEDER, M. J., QYEWUMI, K. AND FREEMAN, D. J.: In vitro toxicity of clozapine metabolites. Clin. Pharmacol. Ther. 59: PII-12, 1996.
31. TURBAY, D., DELGADO, J. C., CORZO, D., AWDEH, Z., ALPER, C., LIEBERMAN, J. AND YUNIS, E. J.: Association of tumor necrosis factor (TNF) varients with clozapine-induced agranulocytosis in two different ethnic groups. J. Invest. Med. 44: PP202, 1996.
32. UETRECHT, J. P.: Metabolism of clozapine by neutrophils: Possible implications for clozapine-induced agranulocytosis. Drug Safety 7 (Suppl. 1): 51-56, 1992.
33. WILSON, A. AND DUFF, G. W.: Genetic traits in common diseases. Br. Med. J. 310: 1482-1483, 1995.
34. XU, Y. AND CZAJA, M. J.: Glutathione (GSH) depletion sensitizes liver cells to TNF-α cytotoxicity. Hepatology 24: P238, 1996.
35. ZHANG, G. Q., MCKAY, G., HUBBARD, J. W. AND MIDHA, K. K.: Application of electrospray mass spectrometry in the identification of intact glucuronide and sulphate conjugates of clozapine in the rat. Xenobiotica 26: 541-550, 1996.